MAIJA LAHTELA-KAKKONEN

Yhteystiedot

Avainsanat

Tutkimusryhmät - UEF

• 
  Mikromuovit ja terveys
• 
  Molekyylimallinnuksen ja lääkeainesuunnittelun tutkimusryhmä
• 
  Sirtuiini tutkimusryhmä - Farmasia

Julkaisut

• Pätsi, Henri T.; Kilpeläinen, Tommi P.; Auno, Samuli; Dillemuth, Pyry M. J.; Arja, Khaled; Lahtela-Kakkonen, Maija K.; Myöhänen, Timo T.; Wallén, Erik A. A.. 2021. 2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors Acs medicinal chemistry letters 12 10: 1578-1584. 2021
• Sallomy, Carita; Lahtela-Kakkonen, Maija; Timonen, Juri M. 2021. Recent Advances on Molecular Modeling Studies of Transient Receptor Potential Ankyrin 1 Medicine Research 5 1: 200021. 2021
• Salo-Ahen, Outi MH; Alanko, Ida; Bhadane, Rajendra; Bonvin, Alexandre MJJ; Honorato, Rodrigo Vargas; Hossain, Shakhawath; Juffer, André H; Kabedev, Aleksei; Lahtela-Kakkonen, Maija; Larsen, Anders Støttrup; Lescrinier, Eveline; Marimuthu, Parthiban; Mirza, Muhammad Usman; Mustafa, Ghulam; Nunes-Alves, Ariane; Pantsar, Tatu; Saadabadi, Atefeh; Singaravelu, Kalaimathy; Vanmeert, Michiel. 2021. Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development Processes 9 1: 71. 2021
• Tenhunen, Jonna; Kucera, Tomáš; Huovinen, Marjo; Küblbeck, Jenni; Bisenieks, Egils; Vigante, Brigita; Ogle, Zaiga; Duburs, Gunars; Doležal, Martin; Moaddel, Ruin; Lahtela-Kakkonen, Maija; Rahnasto-Rilla, Minna. 2021. Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells Biomedicine and pharmacotherapy 138: 111452. 2021
• Rahnasto-Rilla, Minna; Järvenpää, Joni; Huovinen, Marjo; Schroderus, Anna-Mari; Ihantola, Emmi-Leena; Küblbeck, Jenni; Khadeer, Mohammed; Moaddel, Ruin; Lahtela-Kakkonen, Maija. 2020. Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities Biomedicine and pharmacotherapy 131: 110701. 2020
• Sirtuin Inhibitors and Activators. Rahnasto-Rilla, Minna; Tyni, Jonna; Lahtela-Kakkonen, Maija / Chemical Epigenetics. 2020. 2020
• Takkinen, Taru; Siitonen, Piia; Taimi, Anna-Kaisa; Hyvärinen, Marja-Leena; Lahtela-Kakkonen, Maija. 2020. Asiakaspalvelun laatu apteekin reseptintoimituksessa - asiakkaiden ja farmaseuttien odotuksia ja kokemuksia Dosis 36 4: 446-467. 2020
• Tenhunen, Jonna; Kokkola, Tarja; Huovinen, Marjo; Rahnasto-Rilla, Minna; Lahtela-Kakkonen, Maija. 2020. Impact of Structurally Diverse BET Inhibitors on SIRT1 Gene 741: 144558. 2020
• Heger, Vladimír; Tyni, Jonna; Hunyadi, Attila; Horáková, Lubica; Lahtela-Kakkonen, Maija; Rahnasto-Rilla, Minna. 2019. Quercetin based derivatives as sirtuin inhibitors Biomedicine and pharmacotherapy 111: 1326-1333. 2019
• Kilpeläinen, TP; Tyni, JK; Lahtela-Kakkonen, MK; Eteläinen, TS; Myöhänen, TT; Wallén, EAA. 2019. Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors Acs medicinal chemistry letters 10 12: 1635-1640. 2019
• Hassannia, B; Wiernicki, B; Ingold, I; Qu, F; Van Herck, S; Tyurina, YY; Bayir, H; Abhari, BA; Angeli, JPF; Choi, S; Meul, E; Heyninck, K; Declerck, K; Chirumamilla, CS; Lahtela-Kakkonen, M; Van Camp, G; Krysko, DV; Ekert, PG; Fulda, S; De Geest, BG; Conrad, M; et al. 2018. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma Journal of clinical investigation 128 8: 3341-3355. 2018
• Kärkkäinen, J; Gynther, M; Kokkola, T; Petsalo, A; Auriola, S; Lahtela-Kakkonen, M; Laine, K; Rautio, J; Huttunen, KM. 2018. Structural properties for selective and efficient L-type amino acid transporter 1 (LAT1) mediated cellular uptake INTERNATIONAL JOURNAL OF PHARMACEUTICS 544 1: 91-99. 2018
• Milenkovic, D; Berghe, WV; Morand, C; Claude, S; van de Sandt, A; Gorressen, S; Monfoulet, LE; Chirumamilla, CS; Declerck, K; Szic, KSV; Lahtela-Kakkonen, M; Gerhauser, C; Merx, MW; Kelm, M. 2018. A systems biology network analysis of nutri(epi)genomic changes in endothelial cells exposed to epicatechin metabolites Scientific Reports 8 1: 15487. 2018
• Rahnasto-Rilla, M; Tyni, J; Huovinen, M; Jarho, E; Kulikowicz, T; Ravichandran, S; Bohr, VA; Ferrucci, L; Lahtela-Kakkonen, M; Moaddel R. 2018. Natural polyphenols as sirtuin 6 modulators. Scientific Reports 8: 4163. 2018
• Vidakovic, Melita; Marinello, Jessica; Kakkonen, Maija L; Matulis, Daumantas; Linkuviene, Vaida; Michel, Benoît Y; Navakauskiene, Ruta; Christodoulou, Michael S; Passarella, Danielle; Klimasauskas, Saulius; Blanquart, Christophe; Cuendet, Muriel; Ovadi, Judit; Poulain, Stéphane; Fontaine-Vive, Fabien; Burger, Alain; Martinet, Nadine. 2018. New Insights into the Epigenetic Activities of Natural Compounds OBM Genetics 2 3: 029. 2018
• Mellini Paolo, Itoh Yukihiro, Tsumoto Hiroki, Li Ying, Suzuki Miki, Tokuda Natsuko, Kakizawa Taeko, Miura Yuri, Takeuchi Jun, Lahtela-Kakkonen Maija, Suzuki Takayoshi. 2017. Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, "selectivity pocket" and NAD+-binding site. Chemical science 8 9: 6400-6408. 2017
• Rahnasto-Rilla Minna K, McLoughlin Padraig, Kulikowicz Tomasz, Doyle Maire, Bohr Vilhelm A, Lahtela-Kakkonen Maija, Ferrucci Luigi, Hayes Maria, Moaddel Ruin. 2017. The Identification of a SIRT6 Activator from Brown Algae Fucus distichus. Marine Drugs 15 6: 190. 2017
• Carafa Vincenzo, Rotili Dante, Forgione Mariantonietta, Cuomo Francesca, Serretiello Enrica, Hailu Gebremedhin S, Jarho Elina, Lahtela-Kakkonen Maija, Mai Antonello, Altucci Lucia. 2016. Sirtuin functions and modulation: from chemistry to the clinic. Clinical Epigenetics 8: 61. 2016
• Heyninck Karen, Sabbe Linde, Chirumamilla Chandra S, Szarc Vel Szic Katarzyna, Vander Veken Pieter, Lemmens Kristien J, Lahtela-Kakkonen Maija, Naulaerts Stefan, Op de Beeck Ken, Laukens Kris, Van Camp Guy, Weseler Antje R, Bast Aalt, Haenen Guido R, Haegeman Guy, Vanden Berghe Wim. 2016. Withaferin A induces heme oxygenase (HO-1) expression in endothelial cells via activation of the Keap1/Nrf2 pathway. BIOCHEMICAL PHARMACOLOGY 109: 48-61. 2016
• Hytti Maria, Tokarz P, Määttä E, Piippo Niina, Korhonen Eveliina, Suuronen T, Honkakoski Paavo, Kaarniranta Kai, Lahtela-Kakkonen Maija, Kauppinen Anu. 2016. Inhibition of BET bromodomains alleviates inflammation in human RPE cells. BIOCHEMICAL PHARMACOLOGY 110-111: 71-79. 2016
• Koistinen Hannu, Wallén Erik, Ylikangas Henna, Meinander Kristian, Lahtela-Kakkonen Maija, Närvänen Ale, Stenman Ulf-Håkan. 2016. Development of molecules stimulating the activity of KLK3 - an update. BIOLOGICAL CHEMISTRY 397 12: 1229-1235. 2016
• Rahnasto-Rilla Minna, Lahtela-Kakkonen Maija, Moaddel Ruin. 2016. Sirtuin 6 (SIRT6) Activity Assays. Teoksessa: Sarkar Sibaji (toim.) Histone Deacetylases : Methods and Protocols, Part II. Springer. Methods in Molecular Biology 1436. s. 259-269. 2016
• Raunio Hannu, Juvonen Risto O, Poso Antti, Lahtela-Kakkonen Maija, Rahnasto-Rilla Minna. 2016. Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes. Drug Metabolism Letters 10 1: 56-64. 2016
• Ylikangas Henna, Mattsson Johanna M, Stenman Ulf-Håkan, Koistinen Hannu, Poso Antti, Lahtela-Kakkonen Maija. 2016. Virtual Screening of Small Drug-Like Compounds Stimulating the Enzymatic Activity of Kallikrein-Related Peptidase3 (KLK3). CHEMMEDCHEM 11 18: 2043-2049. 2016
• Christodoulou Michael S, Calogero Francesco, Baumann Marcus, García-Argáez Aida Nelly, Pieraccini Stefano, Sironi Maurizio, Dapiaggi Federico, Bucci Raffaella, Broggini Gianluigi, Gazzola Silvia, Liekens Sandra, Silvani Alessanda, Lahtela-Kakkonen Maija, Martinet Nadine, Nonell-Canals Alfons, Santamaría-Navarro Eduardo, Baxendale Ian R, Dalla Via Lisa, Passarella Daniele. 2015. Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 92 6: 766-775. 2015
• Kokkola Tarja, Suuronen Tiina, Pesonen Maija, Filippakopoulos Panagis, Salminen Antero, Jarho Elina M, Lahtela-Kakkonen Maija. 2015. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses. CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY 16: 1997-2001. 2015
• Kokkonen Piia, Kokkola Tarja, Suuronen Tiina, Poso Antti, Jarho Elina, Lahtela-Kakkonen Maija. 2015. Virtual screening approach of sirtuin inhibitors results in two new scaffolds. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 76: 27-32. 2015
• Rahnasto-Rilla Minna, Kokkola Tarja, Jarho Elina, Lahtela-Kakkonen Maija, Moaddel Ruin. 2015. N-Acylethanolamines Bind to SIRT6. CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY 17 (2016) 1: 77-81. 2015
• Salminen Kaisa A, Rahnasto-Rilla Minna, Vaananen Raija, Imming Peter, Meyer Achim, Horling Aline, Poso Antti, Laitinen Tuomo, Raunio Hannu, Lahtela-Kakkonen Maija. 2015. Time-dependent inhibition of CYP2C19 by isoquinoline alkaloids: in vitro and in silico analysis. DRUG METABOLISM AND DISPOSITION 43: 1891-1904. 2015
• Kokkonen Piia, Rahnasto-Rilla Minna, Mellini Paolo, Jarho Elina, Lahtela-Kakkonen Maija, Kokkola Tarja. 2014. Studying SIRT6 regulation using H3K56 based substrate and small molecules. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 63: 71-76. 2014
• Seifert Tina, Malo Marcus, Kokkola Tarja, Engen Karin, Fridén-Saxin Maria, Wallén Erik A, Lahtela-Kakkonen Maija, Jarho Elina M, Luthman Kristina. 2014. Chroman-4-one- and Chromone-based Sirtuin 2 Inhibitors with Antiproliferative Properties in Cancer Cells. JOURNAL OF MEDICINAL CHEMISTRY 57: 9870-9888. 2014
• Ylikangas Henna, Malmioja Kalle, Peura Lauri, Gynther Mikko, Nwachukwu Emmanuel O, Leppänen Jukka, Laine Krista, Rautio Jarkko, Lahtela-Kakkonen Maija, Huttunen Kristiina M, Poso Antti. 2014. Quantitative Insight into the Design of Compounds Recognized by the L-Type Amino Acid Transporter 1 (LAT1). CHEMMEDCHEM 9: 2699-2707. 2014
• Kokkonen Piia, Mellini Paolo, Nyrhilä Olli, Rahnasto-Rilla Minna, Suuronen Tiina, Kiviranta Päivi, Huhtiniemi Tero, Poso Antti, Jarho Elina, Lahtela-Kakkonen Maija. 2014. Quantitative insights for the design of substrate-based SIRT1 inhibitors. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 59: 12-19. 2014
• Christodoulou Michael S, Thomas Adeline, Poulain Stéphane, Vidakovic Melita, Lahtela-Kakkonen Maija, Matulis Daumantas, Bertrand Philippe, Bartova Eva, Blanquart Christophe, Mikros Emmanuel, Fokialakis Nikolas, Passarella Daniele, Benhida Rachid, Martinet Nadine. 2014. Can we use the epigenetic bioactivity of caloric restriction and phytochemicals to promote healthy ageing?. Medicinal Chemistry Communications 5: 1804-1820. 2014
• Kokkola Tarja, Suuronen Tiina, Molnár Ferdinand, Määttä Juha, Salminen Antero, Jarho Elina M, Lahtela-Kakkonen Maija. 2014. AROS has a context-dependent effect on SIRT1. FEBS LETTERS 588: 1523-1528. 2014
• Heyninck Karen, Lahtela-Kakkonen Maija, van der Veken Pieter, Haegeman Guy, Vanden Berghe Wim. 2014. Withaferin A inhibits NF-kappaB activation by targeting Cysteine 179 in IKKß. BIOCHEMICAL PHARMACOLOGY 91: 501-509. 2014
• Christodoulou Michael S, Sacchetti Alessandro, Ronchetti Valentina, Caufin Stefania, Silvani Alessandra, Lesma Giordano, Fontana Gabriele, Minicone Fabrizio, Riva Benedetta, Ventura Micol, Lahtela-Kakkonen Maija, Jarho Elina, Zuco Valentina, Zunino Franco, Martinet Nadine, Dapiaggi Federico, Pieraccini Stefano, Sironi Maurizio, Dalla Via Lisa, Gia Ornella M, Passarella Daniele. 2013. Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins. BIOORGANIC AND MEDICINAL CHEMISTRY 21: 6920-6928. 2013
• Käsnänen Heikki, Minkkilä Anna, Taupila Susanna, Patel Jayendra Z, Parkkari Teija, Lahtela-Kakkonen Maija, Saario Susanna M, Nevalainen Tapio, Poso Antti. 2013. 1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 49: 423-433. 2013
• Luo Rusong, Laitinen Tuomo, Teng Liyan, Nevalainen Tapio, Lahtela-Kakkonen Maija, Zheng Baofu, Wang Honghai, Poso Antti, Zhang Xuelian. 2013. Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity. LETTERS IN DRUG DESIGN & DISCOVERY 10 7: 640-650. 2013
• Mellini Paolo, Kokkola Tarja, Suuronen Tiina, Salo Heikki S, Tolvanen Laura, Mai Antonello, Lahtela-Kakkonen Maija, Jarho Elina M. 2013. Screen of pseudopeptidic inhibitors of human sirtuins 1-3: Two lead compounds with antiproliferative effects in cancer cells. JOURNAL OF MEDICINAL CHEMISTRY 56 17: 6681-6695. 2013
• Salo Heikki S, Laitinen Tuomo, Poso Antti, Jarho Elina, Lahtela-Kakkonen Maija. 2013. Identification of novel SIRT3 inhibitor scaffolds by virtual screening. BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 23: 2990-2995. 2013
• Fridén-Saxin Maria, Seifert Tina, Rydén Landergren Marie, Suuronen Tiina, Lahtela-Kakkonen Maija, Jarho Elina M, Luthman Kristina. 2012. Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors. JOURNAL OF MEDICINAL CHEMISTRY 55: 7104-7113. 2012
• Kokkonen Piia, Rahnasto-Rilla Minna, Kiviranta Päivi H, Huhtiniemi Tero, Laitinen Tuomo, Poso Antti, Jarho Elina, Lahtela-Kakkonen Maija. 2012. Peptides and pseudopeptides as SIRT6 deacetylation inhibitors. ACS Medicinal Chemistry Letters 3: 969-974. 2012
• Martikainen Laura E, Rahnasto-Rilla Minna, Neshybova Silvie, Lahtela-Kakkonen Maija, Raunio Hannu, Juvonen Risto O. 2012. Interactions of inhibitor molecules with the human CYP2E1 enzyme active site. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 47 5: 996-1005. 2012
• Piia Kokkonen, Minna Rahnasto-Rilla, Päivi Kiviranta, Tero Huhtiniemi, Tuomo Laitinen, Antti Poso, Elina Jarho, Maija Lahtela-Kakkonen. 2012. Peptides and Pseudopeptides as SIRT6 Inhibitors. Teoksessa: (toim.), EFMC-ISMC 2012 22nd International Symposium on Medicinal Chemistry Berlin, Germany, September 2.-6., 2012. ss. -. 2012
• Rotili Dante, Tarantino Domenico, Nebbioso Angela, Paolini Chantal, Huidobro Covadonga, Lara Ester, Mellini Paolo, Lenoci Alessia, Pezzi Riccardo, Giorgia Botta, Lahtela-Kakkonen Maija, Poso Antti, Steinkuhler Christian, Gallinari Paola, De Maria Ruggero, Fraga Mario F, Esteller Manel, Altucci Lucia, Mai Antonello. 2012. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. JOURNAL OF MEDICINAL CHEMISTRY 55: 10937-10947. 2012
• Ylikangas Henna, Mattsson Johanna M, Koistinen Hannu, Poso Antti, Lahtela-Kakkonen Maija. 2012. From Cyclic Peptides to Drug-Like Compounds Stimulating Kallikrein-Related Peptidase 3 (KLK3). Teoksessa: (toim.), FinPharma Doctoral Program (FPDP): 6th Joint Meeting at the University of Turku, August 16-17, 2012, Turku, Finland. ss. 28:327. 2012
• Ylikangas Henna, Peura Lauri, Malmioja Kalle, Leppänen Jukka, Laine Krista, Poso Antti, Lahtela-Kakkonen Maija, Rautio Jarkko. 2012. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2013:48: 523-531. 2012
• Rahnasto Minna K, Raunio Hannu A, Wittekindt Carsten, Salminen Kaisa A, Leppänen Jukka, Juvonen Risto O, Poso Antti, Lahtela-Kakkonen Maija K. 2011. Identification of novel CYP2A6 inhibitors by virtual screening BIOORGANIC AND MEDICINAL CHEMISTRY 19: 7186-7193. 2011
• Sakhteman Amirhossein, Lahtela-Kakkonen Maija, Poso Antti. 2011. Studying the catechol binding cavity in comparative models of human dopamine D2 receptor JOURNAL OF MOLECULAR GRAPHICS AND MODELLING 29 5: 685-692. 2011
• Härkönen Henna H, Mattsson Johanna M, Määttä Juha AE, Stenman Ulf-Håkan, Koistinen Hannu, Matero Sanni, Windshügel Björn, Poso Antti, Lahtela-Kakkonen Maija. 2011. The discovery of compounds that stimulate the activity of kallikrein-related peptidase 3 (KLK3) CHEMMEDCHEM 6 12: 2170-2178. 2011
• Huhtiniemi Tero, Salo Heikki S, Suuronen Tiina, Poso Antti, Salminen Antero, Leppänen Jukka, Jarho Elina, Lahtela-Kakkonen Maija. 2011. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2 JOURNAL OF MEDICINAL CHEMISTRY 54: 6456-6468. 2011
• Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M, Bruijn T, Jääskeläinen S, Poso A, Salminen A, Leppänen J & Jarho E. 2010. N(epsilon)-modified lysine containing inhibitors for SIRT1 and SIRT2. BIOORGANIC AND MEDICINAL CHEMISTRY 18: 5616-5625. 2010
• Kalliokoski T, Salo HS, Lahtela-Kakkonen M & Poso A. 2010. ChemInform Abstract: The effect of ligand-based tautomer and protomer prediction on structure-based virtual screening. CHEMINFORM 13: DOI: 10.1002/chin.201013212. 2010
• Kalliokoski T, Salo HS, Lahtela-Kakkonen M, Poso A. 2009. The effect of ligand-based tautomer and protomer prediction on structure-based virtual screening. JOURNAL OF CHEMICAL INFORMATION AND MODELING 49: 2742-2748. 2009
• Myllymäki MJ, Käsnänen H, Kataja AO, Lahtela-Kakkonen M, Saario SM, Poso A, Koskinen AMP. 2009. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 44: 4179-4191. 2009
• Paakkunainen M, Matero S, Ketolainen J, Lahtela-Kakkonen M, Poso A, Reinikainen S-P. 2009. Uncertainty in dissolution test of drug release. CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS 97: 82-90. 2009
• Matero S, Reinikainen S-P, Lahtela-Kakkonen M, Korhonen O, Ketolainen J, Poso A. 2008. Estimation of drug release profiles of a heterogeneous set of drugs from a hydrophobic matrix tablet using molecular descriptors JOURNAL OF CHEMOMETRICS 22: 653-660. 2008
• Matero S, Poutiainen S, Leskinen J, Hakulinen M, Lahtela-Kakkonen M, Ketolainen J, Lappalainen R, Järvinen K & Poso A. 2008. Determination of batch-to-batch variation for fluidized bed granulation, Eur J Pharm Sci Vol 34 (1 Suppl 1). Abstracts: 19th Helsinki Drug Research June 9-11. S31. 2008
• Kiviranta PH, Salo HS, Leppänen J, Rinne VM, Kyrylenko S, Kuusisto E, Suuronen T, Salminen A, Poso A, Lahtela-Kakkonen M, Wallén EAA. 2008. Characterization of the binding properties of SIRT2 inhibitors with a N-(3-phenylpropenoyl)-glycine tryptamide backbone. BIOORGANIC AND MEDICINAL CHEMISTRY 16: 8054-8062. 2008
• Jyrkkärinne J, Windshügel B, Rönkkö T, Tervo AJ, Küblbeck J, Lahtela-Kakkonen M, Sippl W, Poso A, Honkakoski P. 2008. Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship. JOURNAL OF MEDICINAL CHEMISTRY 51: 7181-7192. 2008
• Huhtiniemi T, Suuronen T, Rinne VM, Wittekindt C, Lahtela-Kakkonen M, Jarho E, Wallén EAA, Salminen A, Poso A, Leppänen J. 2008. Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors. JOURNAL OF MEDICINAL CHEMISTRY 51: 4377-4380. 2008
• Matero S, Pajander J, Soikkeli A-M, Reinikainen S-P, Lahtela-Kakkonen M, Korhonen O, Ketolainen J, Poso A. 2007. Predicting the drug concentration in starch acetate matrix tablets from ATR-FTIR spectra using multi-way methods ANALYTICA CHIMICA ACTA (AMSTERDAM) 595: 190-197. 2007
• Huhtiniemi T, Wittekindt C, Laitinen T, Leppänen J, Salminen A, Poso A, Lahtela-Kakkonen M. 2006. Comparative and pharmacophore model for deacetylase SIRT1. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN 20: 589-599. 2006
• Kiviranta PH, Leppänen J, Kyrylenko S, Salo HS, Lahtela-Kakkonen M, Tervo AJ, Wittekindt C, Suuronen T, Kuusisto E, Järvinen T, Salminen A, Poso A, Wallén EAA. 2006. N,N'-bisbenzylidenebenzene-1,4-diamines and N,N'-bisbenzylidenenaphthalene-1,4-diamines as sirtuin type 2 (SIRT2) inhibitors. JOURNAL OF MEDICINAL CHEMISTRY 49: 7907-7911. 2006
• Matero S, Lahtela-Kakkonen M, Korhonen O, Ketolainen J, Lappalainen R, Poso A. 2006. Chemical space of orally active compounds. CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS 84: 134-141. 2006
• Salo OMH, Savinainen JR, Parkkari T, Nevalainen T, Lahtela-Kakkonen M, Gynther J, Laitinen JT, Järvinen T, Poso A. 2006. 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data JOURNAL OF MEDICINAL CHEMISTRY 49: 554-566. 2006
• Salo OMH, Raitio KH, Savinainen JR, Nevalainen T, Lahtela-Kakkonen M, Laitinen JT, Järvinen T, Poso A. 2005. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor JOURNAL OF MEDICINAL CHEMISTRY 48: 7166-7171. 2005
• Salo OMH, Lahtela-Kakkonen M, Gynther J, Järvinen T, Poso A. 2004. Development of a 3D model for the human cannabinoid CB1 receptor JOURNAL OF MEDICINAL CHEMISTRY 47: 3048-3057. 2004
• Tuovinen L, Peltonen S, Liikola M, Hotakainen M, Lahtela-Kakkonen M, Poso A, Järvinen K. 2004. Drug release from starch-acetate microparticles and films with and without incorporated alfa-amylase. BIOMATERIALS 25: 4355-4362. 2004
• Lahtela-Kakkonen Maija, Tappura Kirsi,. 2001. Soft-core potentials for gromacs. Teoksessa: (toim.), World Chemistry Congress. ss. 345. 2001